Dialysis Unit, Nephrocare Vila Franca de Xira, Praça Bartolomeu Dias, lote 3 r/c, 2600-063, Vila Franca de Xira, Portugal.
Dialysis Unit, Dialverca, Forte da Casa, Portugal.
J Bone Miner Metab. 2020 Mar;38(2):205-212. doi: 10.1007/s00774-019-01041-9. Epub 2019 Sep 5.
Bone fractures are an important cause of morbidity and mortality in hemodialysis (HD) patients. The aim of this study was to quantify the incidence of fractures in a cohort of prevalent HD patients and evaluate its relationship with possible risk factors. We performed a retrospective analysis of 341 patients, since they started HD (median of 51 months). Demographic, clinical, and biochemical parameters as well as vascular calcifications (VC) were evaluated. Fifty-seven episodes of fracture were identified with a median HD vintage of 47 months (incidence rate of 31 per 1000 person-years). Age (p < 0.001), female gender (p < 0.001), lower albumin (p = 0.02), and higher VC score (p < 0.001) were independently associated with increased risk of fracture, while active vitamin D therapy (p = 0.03) was associated with decreased risk. A significantly higher risk of incident fracture was also associated with higher values of bone-specific alkaline phosphatase (bALP) (p = 0.01) and intact parathyroid hormone (iPTH) levels either < 300 pg/mL (p = 0.02) or > 800 pg/mL (p < 0.001) compared with 300-800 pg/mL. In conclusion, bone fracture incidence in HD patients is high and its risk increases with age, female gender, lower serum albumin, and with the presence of more VC. Prevalent HD patients with low or high iPTH levels or increased bALP also had a higher fracture risk. Therapy with active vitamin D seems to have a protective role. Assessment of fracture risk and management in dialysis patients at greatest risk requires further study.
骨折是血液透析(HD)患者发病率和死亡率的重要原因。本研究旨在量化一组现患 HD 患者骨折的发生率,并评估其与可能的危险因素的关系。我们对 341 名患者进行了回顾性分析,从他们开始 HD(中位数为 51 个月)开始。评估了人口统计学、临床和生化参数以及血管钙化(VC)。共发现 57 例骨折,HD 年龄中位数为 47 个月(发生率为 31/1000 人年)。年龄(p<0.001)、女性(p<0.001)、较低的白蛋白(p=0.02)和较高的 VC 评分(p<0.001)与骨折风险增加独立相关,而活性维生素 D 治疗(p=0.03)与骨折风险降低相关。骨特异性碱性磷酸酶(bALP)(p=0.01)和完整甲状旁腺激素(iPTH)水平较高(分别为<300 pg/mL(p=0.02)或>800 pg/mL(p<0.001)与 300-800 pg/mL 相比,骨折的发生率也显著增加。总之,HD 患者的骨折发生率较高,其风险随年龄、女性、血清白蛋白降低和 VC 增加而增加。低或高 iPTH 水平或 bALP 升高的现患 HD 患者骨折风险也较高。活性维生素 D 治疗似乎具有保护作用。需要进一步研究评估风险较高的透析患者的骨折风险和管理。